U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination
    • Showing Current items.

    APOL1 apolipoprotein L1 [ Homo sapiens (human) ]

    Gene ID: 8542, updated on 4-Nov-2024

    GeneRIFs: Gene References Into Functions

    GeneRIFPubMed TitleDate
    APOL1 polymorphisms are not influencing acute coronary syndrome risk in Czech males.

    APOL1 polymorphisms are not influencing acute coronary syndrome risk in Czech males.
    Hubacek JA, Adamkova V, Lanska V, Stanek V, Mrazkova J, Gebauerova M, Kettner J, Kautzner J, Pitha J., Free PMC Article

    11/4/2024
    Interferon-gamma induces combined pyroptotic angiopathy and APOL1 expression in human kidney disease.

    Interferon-γ induces combined pyroptotic angiopathy and APOL1 expression in human kidney disease.
    Juliar BA, Stanaway IB, Sano F, Fu H, Smith KD, Akilesh S, Scales SJ, El Saghir J, Bhatraju PK, Liu E, Yang J, Lin J, Eddy S, Kretzler M, Zheng Y, Himmelfarb J, Harder JL, Freedman BS., Free PMC Article

    07/11/2024
    African ancestry-derived APOL1 risk genotypes show proximal epigenetic associations.

    African ancestry-derived APOL1 risk genotypes show proximal epigenetic associations.
    Breeze CE, Lin BM, Winkler CA, Franceschini N., Free PMC Article

    07/9/2024
    Evaluating ApoL1 Genetic Testing Policy Options for Transplant Centers: A Delphi Consensus Panel Project with Stakeholders.

    Evaluating ApoL1 Genetic Testing Policy Options for Transplant Centers: A Delphi Consensus Panel Project with Stakeholders.
    McIntosh T, Walsh H, Baldwin K, Iltis A, Mohan S, Sawinski D, Goodman M, DuBois JM.,

    06/16/2024
    IFI16 Is Indispensable for Promoting HIF-1alpha-Mediated APOL1 Expression in Human Podocytes under Hypoxic Conditions.

    IFI16 Is Indispensable for Promoting HIF-1α-Mediated APOL1 Expression in Human Podocytes under Hypoxic Conditions.
    Randle RK, Amara VR, Popik W., Free PMC Article

    04/2/2024
    Phenome-wide analysis reveals epistatic associations between APOL1 variants and chronic kidney disease and multiple other disorders.

    Phenome-wide analysis reveals epistatic associations between APOL1 variants and chronic kidney disease and multiple other disorders.
    Adamson WE, Noyes H, Johnson P, Cooper A, Monckton DG, Ogunsola J, Beckett-Hill G, Sullivan M, Mark P, Parekh RS, MacLeod A., Free PMC Article

    03/18/2024
    Genome-Wide Polygenic Risk Score for CKD in Individuals with APOL1 High-Risk Genotypes.

    Genome-Wide Polygenic Risk Score for CKD in Individuals with APOL1 High-Risk Genotypes.
    Vy HMT, Coca SG, Sawant A, Sakhuja A, Gutierrez OM, Cooper R, Loos RJF, Horowitz CR, Do R, Nadkarni GN.,

    03/12/2024
    APOL1-mediated monovalent cation transport contributes to APOL1-mediated podocytopathy in kidney disease.

    APOL1-mediated monovalent cation transport contributes to APOL1-mediated podocytopathy in kidney disease.
    Datta S, Antonio BM, Zahler NH, Theile JW, Krafte D, Zhang H, Rosenberg PB, Chaves AB, Muoio DM, Zhang G, Silas D, Li G, Soldano K, Nystrom S, Ferreira D, Miller SE, Bain JR, Muehlbauer MJ, Ilkayeva O, Becker TC, Hohmeier HE, Newgard CB, Olabisi OA., Free PMC Article

    03/4/2024
    HIF-2alpha/LINC02609/APOL1-mediated lipid storage promotes endoplasmic reticulum homeostasis and regulates tumor progression in clear-cell renal cell carcinoma.

    HIF-2α/LINC02609/APOL1-mediated lipid storage promotes endoplasmic reticulum homeostasis and regulates tumor progression in clear-cell renal cell carcinoma.
    Xiao H, Qu Y, Li H, Zhang Y, Fei M, Liang C, Yang H, Zhang X., Free PMC Article

    02/29/2024
    Idiopathic collapsing glomerulopathy is associated with APOL1 high-risk genotypes or Mendelian variants in most affected individuals in a highly admixed population.

    Idiopathic collapsing glomerulopathy is associated with APOL1 high-risk genotypes or Mendelian variants in most affected individuals in a highly admixed population.
    Neves PD, Watanabe A, Watanabe EH, Narcizo AM, Nunes K, Lerario AM, Ferreira FM, Cavalcante LB, Wongboonsin J, Malheiros DM, Jorge LB, Sampson MG, Noronha IL, Onuchic LF.

    02/27/2024
    Apolipoprotein L1 (APOL1) renal risk variant-mediated podocyte cytotoxicity depends on African haplotype and surface expression.

    Apolipoprotein L1 (APOL1) renal risk variant-mediated podocyte cytotoxicity depends on African haplotype and surface expression.
    Gupta N, Waas B, Austin D, De Mazière AM, Kujala P, Stockwell AD, Li T, Yaspan BL, Klumperman J, Scales SJ., Free PMC Article

    02/21/2024
    APOL1 Gene Variants and Risk for Cardiovascular Disease.

    APOL1 Gene Variants and Risk for Cardiovascular Disease.
    Duran CE, Estacio M, Espinosa D, Manzi E, Posada JG, Mesa L, Schweineberg J.

    12/26/2023
    APOL1 Risk Variants Associate With the Prevalence of Stroke in African American Current and Past Smokers.

    APOL1 Risk Variants Associate With the Prevalence of Stroke in African American Current and Past Smokers.
    Rakic JM, Pullinger CR, Van Blarigan EL, Movsesyan I, Stock EO, Malloy MJ, Kane JP., Free PMC Article

    12/21/2023
    Strong protective effect of the APOL1 p.N264K variant against G2-associated focal segmental glomerulosclerosis and kidney disease.

    Strong protective effect of the APOL1 p.N264K variant against G2-associated focal segmental glomerulosclerosis and kidney disease.
    Gupta Y, Friedman DJ, McNulty MT, Khan A, Lane B, Wang C, Ke J, Jin G, Wooden B, Knob AL, Lim TY, Appel GB, Huggins K, Liu L, Mitrotti A, Stangl MC, Bomback A, Westland R, Bodria M, Marasa M, Shang N, Cohen DJ, Crew RJ, Morello W, Canetta P, Radhakrishnan J, Martino J, Liu Q, Chung WK, Espinoza A, Luo Y, Wei WQ, Feng Q, Weng C, Fang Y, Kullo IJ, Naderian M, Limdi N, Irvin MR, Tiwari H, Mohan S, Rao M, Dube GK, Chaudhary NS, Gutiérrez OM, Judd SE, Cushman M, Lange LA, Lange EM, Bivona DL, Verbitsky M, Winkler CA, Kopp JB, Santoriello D, Batal I, Pinheiro SVB, Oliveira EA, Simoes E Silva AC, Pisani I, Fiaccadori E, Lin F, Gesualdo L, Amoroso A, Ghiggeri GM, D'Agati VD, Magistroni R, Kenny EE, Loos RJF, Montini G, Hildebrandt F, Paul DS, Petrovski S, Goldstein DB, Kretzler M, Gbadegesin R, Gharavi AG, Kiryluk K, Sampson MG, Pollak MR, Sanna-Cherchi S., Free PMC Article

    12/6/2023
    Genetic Inhibition of APOL1 Pore-Forming Function Prevents APOL1-Mediated Kidney Disease.

    Genetic Inhibition of APOL1 Pore-Forming Function Prevents APOL1-Mediated Kidney Disease.
    Hung AM, Assimon VA, Chen HC, Yu Z, Vlasschaert C, Triozzi JL, Chan H, Wheless L, Wilson O, Shah SC, Mack T, Thompson T, Matheny ME, Chandrasekar S, Mozaffari SV, Chung CP, Tsao P, Susztak K, Siew ED, Estrada K, Gaziano JM, Graham RR, Tao R, Hoek M, Robinson-Cohen C, Green EM, Bick AG, Million Veteran Program., Free PMC Article

    12/5/2023
    Association of Recipient APOL1 Kidney Risk Alleles With Kidney Transplant Outcomes.

    Association of Recipient APOL1 Kidney Risk Alleles With Kidney Transplant Outcomes.
    Roy N, Morales-Alvarez MC, Anis KH, Goral S, Doria C, Kopp JB, Winkler CA, Feng R, Rosas SE.,

    12/1/2023
    Association between APOL1 risk variants and the occurrence of sepsis in Black patients hospitalized with infections: a retrospective cohort study.

    Association between APOL1 risk variants and the occurrence of sepsis in Black patients hospitalized with infections: a retrospective cohort study.
    Jiang L, Liu G, Oeser A, Ihegword A, Dickson AL, Daniel LL, Hung AM, Cox NJ, Chung CP, Wei WQ, Stein CM, Feng Q., Free PMC Article

    11/14/2023
    Multi-ancestry GWAS analysis identifies two novel loci associated with diabetic eye disease and highlights APOL1 as a high risk locus in patients with diabetic macular edema.

    Multi-ancestry GWAS analysis identifies two novel loci associated with diabetic eye disease and highlights APOL1 as a high risk locus in patients with diabetic macular edema.
    Stockwell AD, Chang MC, Mahajan A, Forrest W, Anegondi N, Pendergrass RK, Selvaraj S, Reeder J, Wei E, Iglesias VA, Creps NM, Macri L, Neeranjan AN, van der Brug MP, Scales SJ, McCarthy MI, Yaspan BL., Free PMC Article

    08/31/2023
    Clinical and Genetic Characteristics of CKD Patients with High-Risk APOL1 Genotypes.

    Clinical and Genetic Characteristics of CKD Patients with High-Risk APOL1 Genotypes.
    Elliott MD, Marasa M, Cocchi E, Vena N, Zhang JY, Khan A, Krishna Murthy S, Bheda S, Milo Rasouly H, Povysil G, Kiryluk K, Gharavi AG., Free PMC Article

    08/25/2023
    Fetal High-Risk APOL1 Genotype Increases Risk for Small for Gestational Age in Term Infants Affected by Preeclampsia.

    Fetal High-Risk APOL1 Genotype Increases Risk for Small for Gestational Age in Term Infants Affected by Preeclampsia.
    Azhibekov T, Durodoye R, Miller AK, Simpson CL, Davis RL, Williams SM, Bruggeman LA., Free PMC Article

    08/23/2023
    Editing of APOL1 mRNA reduces APOL1 expression and activation of innate immunity.

    Editing of APOL1 mRNA reduces APOL1 expression and activation of innate immunity.
    Karttunen H, Ross MJ.

    07/25/2023
    The metabolic effects of APOL1 in humans.

    The metabolic effects of APOL1 in humans.
    Adeva-Andany MM, Funcasta-Calderón R, Fernández-Fernández C, Ameneiros-Rodríguez E, Vila-Altesor M, Castro-Quintela E., Free PMC Article

    07/23/2023
    Hypoxia hits APOL1 in the kidney.

    Hypoxia hits APOL1 in the kidney.
    Grampp S, Krüger R, Lauer V, Uebel S, Knaup KX, Naas J, Höffken V, Weide T, Schiffer M, Naas S, Schödel J.

    06/26/2023
    Apolipoprotein L1 gene variants and kidney disease in patients with HIV: a systematic review and meta-analysis.

    Apolipoprotein L1 gene variants and kidney disease in patients with HIV: a systematic review and meta-analysis.
    Waziri B, Raji YE, Ekrikpo UE, Naicker S.

    06/2/2023
    Implementation of a culturally competent APOL1 genetic testing programme into living donor evaluation: A two-site, non-randomised, pre-post trial design.

    Implementation of a culturally competent APOL1 genetic testing programme into living donor evaluation: A two-site, non-randomised, pre-post trial design.
    Smith JD, Agrawal A, Wicklund C, Duquette D, Friedewald J, Rasmussen LV, Gacki-Smith J, Tandon SD, Muhammad LN, Yancy CW, Dong S, Cooper M, Gilbert A, Shetty A, Gordon EJ., Free PMC Article

    05/20/2023
    firstprevious page of 12 nextlast